~~<i id='6816BAF12E'><strike id='6816BAF12E'><tt id='6816BAF12E'><pre id='6816BAF12E'></pre></tt></strike></i>~~

Home» comprehensive» Wikipedia

Wikipedia

author：focus 2025-10-02 04:17:38 Page View：157

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Having children helps parents live longer, especially after age 80
Next article： As demand for Covid shots wanes, Moderna seeks its next success

knowledge

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

4:09FormerPresidentDonaldTrumpspeakstosupportersatTrumpNationalGolfClubinBedminsterfollowinghisappea

George Santos makes 1st court appearance after pleading not guilty to 13 counts

1:57GeorgeSantosarrivesatfederalcourtJune30,2023,inCentralIslip,N.Y.JohnMinchillo/APRep.GeorgeSantos

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

MollyFerguson/STATThisweek,apreviewoftheTUDCAstudyinALSandthoughtsonhowitmightimpactAmylyxPharmaceut